The first human trial investigating whether a drug can rejuvenate cells commenced recently, marking a significant moment for the longevity research field. This early-stage clinical trial aims to assess the safety of 'cellular reprogramming' in humans, which is essential for any future claims regarding treatments that may slow or reverse biological aging.
The trial involves an experimental gene therapy targeting eye disorders, including glaucoma, and focuses on three genes that may help restore neuronal function. Life Biosciences, the company sponsoring the trial, was co-founded by David Sinclair, a prominent figure in the longevity field.
While the current phase of the trial is focused solely on safety, any future efficacy trials will need to determine whether the therapy effectively treats glaucoma rather than directly addressing biological aging. Success in this trial could provide critical validation for the concept of cellular reprogramming.
Despite the nascent stage of this field, significant investment has flowed into biotechnology companies pursuing cellular reprogramming. For instance, NewLimit recently reached a valuation of $3.1 billion, while Retro Biosciences, backed by OpenAI CEO Sam Altman, was valued at $1.8 billion. Altos Labs, reportedly funded by Jeff Bezos, launched with $3 billion in 2022.